2018 has been a year of tremendous growth and transition for BioStem Technologies, Inc. (OTC:BSEM). Momentum has been building as they pursue multiple avenues for growth through their three operating subsidiaries, proving extremely capable of executing and hitting their milestones effectively.
Successful Launch of 4 New Products into $812M Market
In Q3 of 2018, Biostem successfully launched four placental-derived tissue allografts that have been developed for the $812M amniotic tissue market. These products are an answer to multiple indications in the ophthalmology, orthopedic and advanced wound care markets. Initial sales have already been made, driving up Q3’s revenue 6x over last year’s Q3.
These four placental-derived tissue allografts are being sold under the brand names RHEO, Vendaje and Vendaje AC. They are a connective tissue allograft flowable matrix derived from human amnion fluid, preserved to maintain the structural properties of the attractive, biologically active elements present in tissue regeneration.
Pre-Clinical Progress in Drug Development
Nesvic Pharmaceuticals, BioStem’s wholly owned subsidiary, is focused on the development of novel reformulated pharmaceutical products that address unmet needs in large. They identify traditional solid dosage drugs and formulate them into easier-to-ingest liquid delivery methods for niche patient groups using the FDA’s 502(b)(2) accelerated pathway.
The first four drugs are focused on the pediatric and geriatric patient population, of which approximately 20% of the targeted patient population has trouble ingesting solid dosage medications. All have received PRE-IND numbers from the FDA already.
Major Advancement with QPI Division
Qualified Pharma Ingredients (QPI), BioStem’s pharmaceutical active ingredient repacking business, expects to launch six new products in the fourth fiscal quarter of 2018, as well as launch of their expanded sales initiative to further broaden their revenue stream.
QPI is a premier supplier of high-quality active pharmaceutical ingredients and other pharmaceutical compounding supplies, and the addition of recent certification from the DEA to handle controlled substances, as well as the acquisition of additional out-of-state licenses, now greatly expands their product line and business throughout the U.S. in Q4 and 2019.